Flagship Pioneering, the bioplatform innovation company, today unveiled Etiome, a company redefining how we detect and preempt disease progression. Etiome's Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcomes for people at risk of chronic or progressive diseases. The AI-powered platform makes it possible to forecast how individuals are likely to progress along the disease continuum, confirm disease biostages with temporally relevant markers, and develop Biostaged Medicines to halt or reverse disease before it becomes debilitating and irreversible. Flagship has initially committed $50 million to Etiome to advance the Temporal Biodynamics™ platform and develop an initial pipeline of preemptive medicines. Etiome was founded from Flagship Pioneering's Preemptive Health and Medicine Initiative, which is pioneering a new field to protect, maintain, or improve people's health before they get sick.

Etiome is redefining how we detect and preempt disease progression to build a healthier future for patients with chronic and progressive diseases. Its Temporal Biodynamics™ platform is the first end-to-end technology to characterize disease with increased resolution over time and accelerate the development of preemptive medicines that promise better health outcomes. The platform makes it possible to predict where individuals are along the disease continuum, confirm disease biostages with temporally relevant markers, and develop Biostaged Medicines to halt or reverse disease before it becomes debilitating and irreversible. Etiome was founded by Flagship Pioneering in 2021.